Award
Definitive Contract #75A50121C00077
HHS Awards $165.34M Contract for Monovalent Vaccine Development
Buyer
Office of Assistant Secretary for Preparedness and Response
Award Amount
$95,592,504.00
Ceiling
$166,898,763.00
Period of Performance
Sep 30, 2021 – Jan 09, 2027
Identifier
75A50121C00077
NAICS
541714
This is a definitive contract awarded by the Department of Health and Human Services (HHS) to the International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization focused on advancing research and development of vaccines against infectious diseases. The contract aims to develop monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease, utilizing recombinant expression of filovirus glycoproteins. This contract is significant for HHS as it contributes to global health security by addressing potential viral outbreaks. The contract was awarded without any set-aside designation under full and open competition, reflecting a commitment to transparency and inclusive procurement. The potential total value of the award is $165,342,408.00, with a current total value of $94,036,149.00. The performance period runs from September 30, 2021, to January 9, 2027, with a potential extension until September 29, 2027. Key subcontractors include Batavia Biosciences, responsible for analytical activities and formulation buffer confirmation, and Seattle Children's Hospital, involved in the Sudan-NHP study. Previous contracts indicative of IAVI's expertise and continuous engagement in vaccine development support this award.
Description
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN